Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes: constipation-predominant, diarrhea-predominant, and mixed. This report focuses on the constipation-predominant (IBS-C) population (and includes IBS-C patients as well as IBS patients without diarrhea, as per ICD-10 codes). Treatments for IBS are limited, and only a few drugs have secured FDA approval for IBS-C. Current options include antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), guanylate cyclase-C agonists (Allergan’s Linzess and Synergy Pharmaceuticals’ Trulance), and bicyclic fatty acids (Takeda’s Amitiza), all of which are only moderately effective in treating the disease. More recently, a 5HT-4 receptor agonist (Alfasigma’s Zelnorm) was relaunched for the treatment of IBS-C. Notably, the agent was first approved in 2002 for the short-term treatment of women with IBS but was withdrawn from the market by Novartis in 2007 because of possible cardiac side effects. Another 5HT-4 receptor agonist, Motegrity, was approved for the treatment of chronic idiopathic constipation, and we expect it to be used off-label for IBS-C.

QUESTIONS ANSWERED

  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed IBS-C (including IBS without diarrhea) patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IBS-C patients?
  • How have Linzess and Trulance been integrated into the treatment algorithm?
  • What proportion of IBS-C patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of IBS-C patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among drug-treated patients with IBS-C?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Table of contents

  • Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis - IBS Without Diarrhea (Including IBS Constipation) - (US)
    • Treatment-Algorithms-Claims-Data-Analysis-IBS-C-US-February-2020

Author(s): Mohit Nasa, MBA

Mohit Nasa is a Lead Insights analyst on the Immune and Inflammatory team at Decision Resources Group and has authored content for indications like asthma and rheumatoid arthritis. He holds a Bachelor’s degree in Pharmacy and has earned his MBA in marketing and CRM from Amity Business School. Prior to joining DRG, Mohit worked as a Senior Business analyst at Novartis where he was responsible for end to end market assessment, reporting analytics and related projects for Novartis’s asthma brand Xolair. Mohit has also worked as Brand Manager at Ozone pharma and an Account Manager for IMS Health.


Related Reports

Irritable Bowel Syndrome | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis - IBS-Diarrhea (US)

Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and...

View Details

Irritable Bowel Syndrome | Treatment Algorithms: Claims Data Analysis | IBS-Diarrhea | US | 2019

Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and ur...

View Details